Clinical trials: Breast Cancer Stage II
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with breast cancer cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment.
- Conditions
- Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01277757
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
RATIONALE: Ondansetron may help lessen or prevent nausea and vomiting in patients undergoing stem cell transplant. PURPOSE: This phase II trial is studying how well ondansetron works in preventing nausea and vomiting in patients…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00795769
- Testing
- ondansetron, survey administration, management of therapy complications
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- Fred Hutchinson Cancer Center
Breast Cancer, Triple Negative Breast Cancer
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
RATIONALE: Everolimus plus Cisplatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NECTAR (NCT01931163)
- Testing
- Everolimus
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Jenny C. Chang, MD
Estrogen Receptor Status, HER2/Neu Negative
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body.
- Conditions
- Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal
- Trial name
- NCT02860000
- Testing
- Alisertib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Breast Cancer, Hormone Changes
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as triptorelin, may protect normal ovarian cells from the side effects of…
- Conditions
- Breast Cancer, Hormone Changes, Drug Toxicity
- Trial name
- NCT00090844
- Testing
- triptorelin
- Where
- 9 sites in United States
- Volunteers
- 49 people
- Sponsor
- University of South Florida
Breast Cancer
Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00675259
- Testing
- bevacizumab, carboplatin, nab-paclitaxel
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Breastcancer
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
Longer first line chemotherapy duration has recently been associated with a modest, but significant improvement in overall survival and a clinically meaningful and statistically significant improvement in progression-free…
- Trial name
- SNAP (NCT01746225)
- Testing
- nab-Paclitaxel
- Where
- 41 sites in Belgium, Ireland and 4 more
- Volunteers
- 258 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
This is an open-label, single arm, multi-center, multi-national, adaptive design, dose-escalation Phase 1/2 study to determine the maximum tolerated dose (MTD) of temsirolimus with daily neratinib, and to determine the safety and…
- Trial name
- NCT01111825
- Testing
- Temsirolimus, Neratinib
- Where
- 12 sites in United States, Denmark and 4 more
- Volunteers
- 99 people
- Sponsor
- Puma Biotechnology, Inc.
Breast Cancer, HER2-negative Breast Cancer
Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer
NSABP FB-9 is a Phase II, multi-center, randomized study of eribulin or weekly paclitaxel followed by doxorubicin and cyclophosphamide (AC) as neoadjuvant therapy for women with HER2-negative, operable and locally advanced breast…
- Trial name
- NCT01705691
- Testing
- Paclitaxel, Eribulin, Doxorubicin
- Where
- 20 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- NSABP Foundation Inc
Metastatic Breast Cancer
A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer
The purpose of this study is to determine if the addition of metformin to standard chemotherapy improves progression free survival in women with metastatic breast cancer.
- Trial name
- NCT01310231
- Testing
- Metformin
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Ozmosis Research Inc.
Advanced Solid Tumors
Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
This study was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LAG525 as a single agent and in combination with PDR001 to adult patients with solid tumors.
- Trial name
- NCT02460224
- Testing
- LAG525, PDR001
- Where
- 24 sites in United States, Australia and 10 more
- Volunteers
- 490 people
- Sponsor
- Novartis Pharmaceuticals
Neoplasms
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Phase Ib / II study to determine the Maximum Tolerated Dose and Recommended Phase II Dose, and to evaluate the safety and antitumour activity, of BI 836845 and everolimus in combination with exemestane in women with HR+/HER2…
- Trial name
- NCT02123823
- Testing
- Everolimus, Exemestane, BI 836845
- Where
- 38 sites in Austria, Belgium and 8 more
- Volunteers
- 164 people
- Sponsor
- Boehringer Ingelheim
Early-Stage Breast Cancer
Proton Therapy for Early Stage Breast Cancer
The purpose of this study is to determine if partial breast proton therapy is effective treatment for early stage breast cancer following lumpectomy.
- Trial name
- NCT00614172
- Testing
- Proton radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Loma Linda University
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
This phase II trial studies how well nab-paclitaxel and alpelisib works in treating patients with triple negative breast cancer with PIK3CA or PTEN alterations that does not respond to anthracycline chemotherapy (anthrocycline…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04216472
- Testing
- Alpelisib, Nab-paclitaxel
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Breast Cancer, Advanced Breast Cancer
Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy
This study has the purpose to demonstrate clinical efficacy of the investigational new drug ertumaxomab in patients with human epidermal growth factor receptor-2 (HER-2/neu) overexpressing (3+ or 2+ with a positive Fluorescence…
- Trial name
- NCT00522457
- Testing
- ertumaxomab
- Where
- 5 sites in United States, Canada
- Volunteers
- 19 people
- Sponsor
- Neovii Biotech
Breast Cancer, Fatigue
Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
RATIONALE: Learning about the long-term effects of adjuvant tamoxifen (T), adjuvant tamoxifen with ovarian function suppression (T+OFS), and exemestane with ovarian function suppression (E+ OFS) on brain function may help doctors…
- Conditions
- Breast Cancer, Fatigue, Sleep Disorders
- Trial name
- Co-SOFT (NCT00659373)
- Testing
- Tamoxifen, triptorelin, Exemestane
- Where
- 15 sites in United States, Canada
- Volunteers
- 86 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Dose dense chemotherapy, which is the term for Adriamycin and Cyclophosphamide (AC) followed by Taxol chemotherapy given every two weeks, is the standard chemotherapy for the treatment of ER+ or PR+ breast cancer.
- Trial name
- NCT00546156
- Testing
- Doxorubicin, Cyclophosphamide, Paclitaxel
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Ian E. Krop, MD, PhD
Neoplasms, Breast
Study Of Ispinesib In Subjects With Breast Cancer
The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is…
- Trial name
- NCT00089973
- Testing
- Ispinesib
- Where
- 13 sites in United States, Belgium and 3 more
- Volunteers
- 50 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
This research study is evaluating how well Breast Cancer responds to preoperative treatment with Endocrine treatment in combination with a drug called Palbociclib or Endocrine treatment alone as possible treatments for Hormone…
- Trial name
- NCT02764541
- Testing
- Letrozole, Tamoxifen, Palbociclib
- Where
- 11 sites in United States
- Volunteers
- 195 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Cancer, Breast Cancer
Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer
There will be two phase II cohorts for pembro plus trastuzumab: one cohort will be for patients with unresectable HER2 overexpressing gastric or GEJ cancers, the other cohort will be for patients with HER2 overexpressing…
- Conditions
- Advanced Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- PembroMab (NCT02318901)
- Testing
- Pembrolizumab, Trastuzumab, ado-trastuzumab emtansine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Western Regional Medical Center